Research Papers:
Long non-coding RNA FEZF1-AS1 facilitates cell proliferation and migration in colorectal carcinoma
Metrics: PDF 2594 views | HTML 3293 views | ?
Abstract
Na Chen1,2,*, Dan Guo3,*, Qiong Xu1,2, Minhui Yang1,2, Dan Wang1, Man Peng1, Yanqing Ding2, Shuang Wang1,2, Jun Zhou1,2
1Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
2Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
3Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
*These authors contributed equally to this work
Correspondence to:
Jun Zhou, e-mail: [email protected]
Shuang Wang, e-mail: [email protected]
Keywords: FEZF1-AS1, FEZF1, colorectal cancer, long non-coding RNA
Received: July 16, 2015 Accepted: January 21, 2016 Published: February 03, 2016
ABSTRACT
Long non-coding RNAs (lncRNA) have been shown to play important roles in the development and progression of cancer. Here, we discovered a novel long noncoding RNA (lncRNA) FEZF1 antisense RNA1 (FEZF1-AS1) is markedly upregulated in human primary colorectal carcinoma (CRC) and associated with CRC metastasis and poor prognosis. Moreover, the downregulation of FEZF1-AS1 expression significantly inhibited the CRC cells proliferation, migration and invasiveness, suppressed S-phase entry in vitro, and repressed tumor growth and metastasis in vivo. In contrast, overexpression of FEZF1-AS1 could promote the aggressive behaviors of CRC cells. We further discovered that the downregulation of FEZF1-AS1 reduced its sense-cognate gene FEZF1 mRNA and protein expression in CRC cells. There was a positive correlation between FEZF1-AS1 and FEZF1 expression in CRC. Moreover, FEZF1 knockdown also significantly suppressed CRC cell proliferation, migration, and invasion. Our findings indicate that the dysregulation of FEZF1-AS1 participates in colorectal tumorigenesis and progression, which might be achieved, at least in part, through FEZF1 induction.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7168